James S. Wysock, MD, MSc, Author at Grand Rounds in Urology

James S. Wysock, MD, MSc

NYU Langone Health

New York, New York

James S. Wysock, MD, MSc, is an Assistant Professor of Urology at NYU Langone Health and Division Chief of Urology at Bellevue Hospital Center in New York City. He received his undergraduate degree in Chemical Engineering from the University of Illinois- Urbana Champaign and his medical degree from Northwestern University Feinberg School of Medicine. He completed his internship and residency training in urology at New York-Presbyterian Hospital in the Brady Department of Urology at Weill Cornell Medical College. He then completed his fellowship in urologic oncology and robotic surgery at NYU Langone, where he also obtained a Master’s of Clinical Investigation.

At NYU Langone Health and Bellevue Hospital, Dr. Wysock provides clinical services for the diagnosis and management of the breadth of urologic malignancies. His clinical research efforts focus on image-guided prostate cancer diagnosis and treatment, including MRI-US fusion biopsy and partial gland prostate ablation techniques.

Talks by James S. Wysock, MD, MSc

PSMA PET for Preoperative Planning of Prostate Cancer: Nodes, Nerves and Margins

Posted by James S. Wysock, MD, MSc | Dec 2024

James Wysock, MD, MS, highlights the transformative role of novel imaging techniques, particularly PSMA PET and MRI, in improving prostate cancer diagnosis, staging, and management.

In this 14-minute presentation, Dr. Wysock explains the combination of PSMA PET and MRI significantly improves the detection of extraprostatic extension and seminal vesicle invasion compared to conventional imaging.

Meta-analyses confirm PSMA PET’s superior accuracy, particularly its high negative predictive value. This suggests that some intermediate-risk men with negative scans might safely omit extended lymph node dissection. This evidence raises important discussions about refining surgical planning and patient consent to balance risks and outcomes.

Wysock addresses emerging data supporting direct prostatectomy based on highly suspicious PSMA PET findings, bypassing biopsies. While controversial, this approach underscores the potential for imaging advancements to redefine standard workflows, especially as artificial intelligence enhances interpretation and decision-making.

Dr. Wysock emphasizes that while PSMA PET and MRI improve staging and management, these tools are still primarily validated in high-risk populations, with sensitivity challenges in lower-risk groups. The evolving role of advanced imaging, coupled with ongoing technological progress, promises to reshape prostate cancer treatment pathways.

The Application of Stimulated Raman Histology to Urologic Malignancies – Human and Artificial Intelligent Assessment

Posted by James S. Wysock, MD, MSc | Aug 2024

James S. Wysock, MD, MSc, explores Stimulated Raman Histology (SRH) in diagnosing and managing urologic malignancies, emphasizing the role of both human and artificial intelligence (AI) assessments. SRH, a cutting-edge imaging technique, provides rapid, label-free histological images of tissues, enabling real-time intraoperative diagnosis. Dr. Wysock highlights SRH’s high specificity and sensitivity in identifying cancerous tissues, potentially reducing reliance on frozen sections and improving surgical outcomes.

Dr. Wysock discusses integrating AI into SRH image analysis, including creating training datasets, validation studies, and clinical trials. The potential for AI to enhance diagnostic precision and minimize human error is a key focus. Data show that SRH, combined with AI assessment, significantly improves the accuracy of margin detection during prostate and kidney cancer surgeries.

Multicenter Clinical Trial of Real-Time Prostate Cancer Diagnosis Using Optical Spectroscopy Guided Prostate Biopsy

Posted by James S. Wysock, MD, MSc | Sep 2019

James S. Wysock, MD, MSc, discusses the Phase I trial of the ClariCore Optical Biopsy system. He outlines the limited efficacy of transrectal ultrasound (TRUS) prostate biopsies, the use of optical spectroscopy to detect Gleason patterns, and details the function and trial performance of the system.